{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Maiorano BA"],"pubmed_abstract":["Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC."],"journal":["Frontiers in oncology"],"pagination":["1254906"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10535083"],"repository":["biostudies-literature"],"pubmed_title":["Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?"],"pmcid":["PMC10535083"],"pubmed_authors":["Maiello E","Roviello G","Maiorano BA","Catalano M"],"additional_accession":[]},"is_claimable":false,"name":"Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?","description":"Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-05T12:14:38.347Z","creation":"2025-02-19T00:00:55.489Z"},"accession":"S-EPMC10535083","cross_references":{"pubmed":["37781180"],"doi":["10.3389/fonc.2023.1254906"]}}